NASH is one of the leading causes of chronic liver disease with the potential of evolving
towards end-stage liver disease and HCC, even in the absence of cirrhosis. Apart from
becoming an increasingly prevalent indication for liver transplantation in cirrhotic and HCC
patients, its burden on the healthcare system is also exerted by the increased number of
noncirrhotic NASH patients. Intermittent fasting has recently gained more interest in the
scientific community as a possible treatment approach for different components of metabolic …